Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723177 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00723177 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 30 participants.
The verdict
NCT00723177, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration. The present study is designed to evaluate the effectiveness of AV411 to alter opioid-induced withdrawal symptoms.
Interventions
- DRUG AV411
- DRUG Placebo (PCB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723177
The ClinicalTrials.gov registry entry for NCT00723177 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AV411 is the first listed.
NCT00723177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00723177 about?
NCT00723177 is a clinical study titled "Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal". Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration. The present study is designed to evaluate the effectiveness of AV411 to alter opioid-induced withdrawal symptoms.
What is the current status of trial NCT00723177?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-10. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00723177?
The interventions under investigation include: AV411 (DRUG), Placebo (PCB) (DRUG).
Who is sponsoring clinical trial NCT00723177?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.